Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Upon execution of the Biogen Agreement, Biogen paid us an upfront payment of $45.0 million as prepayment for candidate development activities.”
FILING10-K0001628280-26-012000cik 0001662579disclosed by CCCC
“We currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.”
FILING10-K0001714899-25-000066cik 0001714899disclosed by DNLI
“On February 14, 2025, we entered into a License and Collaboration Agreement (the "Biogen Agreement") with Biogen International GmbH ("Biogen") for the joint development and commercialization of zorevunersen and other compounds targeting the SCN1A gene (the "Licensed Product").”
FILING10-K0001193125-26-108362cik 0001623526disclosed by STOK
“In September 2016, the Company entered into an asset purchase agreement (the "Biogen Agreement") with Biogen MA Inc. ("Biogen") to acquire all of Biogen's right, title and interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights, clinical data, know-how, and clinical drug supply.”
FILING10-K0001104659-26-019168cik 0001730430disclosed by KNSA
“In March 2025, we acquired from Biogen the regulatory and commercial rights in the United States for Tofidence , a biosimilar to Actemra 2 (tocilizumab), for intravenous infusion.”
FILING10-K0001628280-26-011125cik 0001821825disclosed by OGN
“In September 2023, we entered into the Biogen Agreement with Biogen to research, develop, make, use, offer, sell and import products or processes containing or using an engineering T-cell modified with an mRNA comprising, or encoding a protein comprising, certain sequences licensed under the Biogen Agreement for the prevention, treatment, palliation and management of autoimmune diseases and disorders, excluding cancers, neoplastic disorders, and paraneoplastic disorders.”
FILING10-K0001453687-26-000064cik 0001453687disclosed by RNAC
“In 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our agreements with Biogen and Novartis, respectively.”
FILING10-K0000874015-26-000115cik 0000874015disclosed by IONS
“In May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies.”
FILING10-K0000875045-26-000013cik 0000875045
“In October 2025 we entered into a research collaboration with Dayra to discover and develop oral macrocyclic peptides for priority targets in immunological conditions.”
FILING10-K0000875045-26-000013cik 0000875045
“In October 2025 we entered into a license agreement with Vanqua granting us exclusive worldwide rights to further develop, manufacture and commercialize Vanqua's preclinical oral C5aR1 antagonist compound.”
FILING10-K0000875045-26-000013cik 0000875045
“LRRK2 Program Manufacturing Biogen will be responsible for delivering all supplies for clinical trials and commercial production for LRRK2 Products, except that we will deliver such supplies until the point of transition which will be mutually agreed by us and Biogen, but in no event later than commencement of activities to support commercial launch, and in any event we retain manufacturing rights for certain independent clinical activities.”
FILING10-K0001714899-25-000066cik 0001714899disclosed by DNLI
“In February 2025 we entered into a funding agreement with Royalty Pharma under which we received $200.0 million in 2025 and will receive up to $50.0 million in 2026 to co-fund our development costs for the litifilimab program.”
FILING10-K0000875045-26-000013cik 0000875045
“For a discussion of our agreements with Biogen related to VUMERITY, including the manufacturing and royalty revenue provisions set forth therein, see the section entitled " Collaborative Arrangements—Biogen " in "Item 1—Business" in this Annual Report.”
FILING10-K0001193125-26-068925cik 0001520262disclosed by ALKS
“We have funded our operations to date primarily from proceeds received under collaboration and license agreements with Sanofi, Lilly and Biogen”
FILINGS-1/A0001193125-26-308330cik 0001853921disclosed by SCTX
“In connection with the initiation of this dosing we paid a $30.0 million milestone payment to MorphoSys in July 2025.”
FILING10-K0000875045-26-000013cik 0000875045
“Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, which became effective as of January 2026.”
FILING10-K0000875045-26-000013cik 0000875045
“We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD.”
FILING10-K0000875045-26-000013cik 0000875045
“We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD.”
FILING10-K0000875045-26-000013cik 0000875045
“While Biogen is obligated to reimburse us for the costs of supply related to marketing and sales in the Biogen Territory, we are required to fund the initial cash payments to third-party contract manufacturing organizations prior to receiving reimbursement from Biogen.”
FILING10-K0001356576-26-000011cik 0001356576disclosed by SUPN
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 215.91 · gapped below the open, then crossed back over prior close. High/low 216.49 at 2:00 pm ET, 214.35 at 10:00 am ET.
Biogen Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Biogen Inc. has 13 disclosed suppliers and 6 disclosed customers. Each one is named in an SEC filing, either Biogen Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
BIIB (Biogen Inc.) has 13 disclosed suppliers and 6 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CCCC −0.53%, in healthcare.